Alfred Alfred Nijkerk Pharm.D.

CEO

Alfred holds a MSc in Pharmacy and a PharmD from Utrecht University. Starting as an Industrial Pharmacist, he founded several pharmaceutical contract manufacturing companies before founding VenGen, a hands-on investors and life sciences start-up management company, in 2001. Since then VenGen co-founded several life science ventures, amongst which FlexGen, DiagnOptics and to-BBB technologies. Alfred was to-BBB's Chief Business Officer from founding until January 1st, 2008.

  

 

Farid Farid El Oualid Ph.D.

CSO

Farid El Oualid received his PhD in Bioorganic Chemistry in 2005 from Leiden University. After his PhD, Farid performed post-doctoral research at Oxford University and it was during this period that he started getting interested in the emerging Ubiquitin Proteasome Field. In 2008 he joined the Netherlands Cancer Institute where he focused on the development of chemical technologies for ubiquitin(-like protein) based research tools. Based on this, he co-founded UbiQ in 2010 where he is responsible for general lab management and product development.

  

 

Boris  Boris Rodenko Ph.D.

VP Translational Drug Discovery

Boris is adamant to tackle medical needs with chemical solutions. At UbiQ Therapeutics he leads the drug discovery team, aimed at synthesising functionalised compounds, executing biochemical and cellular screening and performing SAR analysis to support hit-to-lead activities.

Boris has worked in (academic) drug discovery ever since receiving his PhD in Bioorganic Chemistry in 2004 from the University of Amsterdam. He started a programme aimed at developing nucleoside analogues as anti-infective agents at the University of Glasgow. In 2005 he moved to the Netherlands Cancer Institute (NKI) and specialised in the Chemical Biology of the ubiquitin-proteasome-antigen presentation triad. In 2008 Boris was appointed Manager/Consultant High-throughput screening supervising academic drug discovery programmes at the NKI. In 2012 Boris moved to Glasgow as a group leader Chemical Biology and Academic Drug Discovery at the Wellcome Trust Centre for Molecular Parasitology. He used chemical genetics, chemical proteomics and functional genomics to validate a deubiquitinating enzyme in the trypanosome parasite as a tractable drug target, which sparked a lead discovery programme in collaboration with Glaxo-Smith-Kline. In 2015 he co-founded UbiQ Therapeutics with Alfred Nijkerk and Farid El Oualid.

  

 

Alessia Alessia Amore Ph.D.

Senior Scientist

Alessia has received her doctorate in synthetic organic chemistry (2006) from the University of Amsterdam in the group of Prof. Henk Hiemstra. In 2009, after a few years of research in bio-organic (at the VU in Amsterdam, as a Postdoc) and medicinal chemistry (at Dompè, a pharmaceutical company, in Italy), she joined the Chemical Biology group of Prof. Huib Ovaa at the NKI working on projects that merge different branches of science, and to apply chemistry for technology development. She obtained a IEF Marie Curie Fellowship to work on the total synthesis of a MHC class I platform. Besides the research on the MHC platform, she worked on the design and the synthesis of new small drug-like molecules with the aim to discover new drug targets. Since summer 2015, Alessia entered the ubiquitin field by joining UbiQ.

  

founders

UbiQ was founded by Huib Ovaa and Farid El Oualid, two distinguished scientists from the Netherlands Cancer Institute, together with Alfred Nijkerk, an experienced biotech entrepreneur. 

 

Founders Huib Ovaa Ph.D. (professor Chemical Biology, Leiden University)

Scientific co-Founder

Since 2004 Huib is leading a research team specialized in organic synthesis, chemical biology and drug innovation at the Netherlands Cancer Institute (NKI) specializing in the design and development of diagnostic and proteomic tools using a variety of approaches, including high-throughput small molecule screening with the ultimate goal of early diagnosis and treatment of cancer. Huib Ovaa is Professor of chemical biology of post translational protein modifications at the faculty of mathematics and natural sciences of Leiden University.